H. R. 941 
One Hundred Seventeenth Congress 
of the 
United States of America 
AT THE FIRST SESSION 
Begun and held at the City of Washington on Sunday, 
the third day of January, two thousand and twenty-one 
An Act 
To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other 
purposes. 
Be it enacted by the Senate and House of Representatives of 
the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Timely ReAuthorization of Nec-
essary Stem-cell Programs Lends Access to Needed Therapies Act 
of 2021’’ or the ‘‘TRANSPLANT Act of 2021’’. 
SEC. 
2. 
REAUTHORIZATION 
OF 
THE 
C.W. 
BILL 
YOUNG 
CELL 
TRANSPLANTATION PROGRAM. 
(a) ADVISORY COUNCIL MEETINGS.—Subsection (a) of section 
379 of the Public Health Service Act (42 U.S.C. 274k) is amended 
by adding at the end the following new paragraph: 
‘‘(7) The Secretary shall convene the Advisory Council at 
least two times each calendar year.’’. 
(b) INCREASING COLLECTION.— 
(1) TECHNICAL CLARIFICATION.—Effective as if included in 
the enactment of Public Law 114–104 (the Stem Cell Thera-
peutic and Research Reauthorization Act of 2015), the amend-
ment to section 379(d)(2)(B) of the Public Health Service Act 
(42 U.S.C. 274k(d)(2)(B)) in section 2(a)(2) of Public Law 114– 
104 is amended by inserting ‘‘goal of increasing collections 
of high quality’’ before ‘‘cord blood units,’’. 
(2) ELIMINATING DEADWOOD.—Subparagraph (B) of section 
379(d)(2) of the Public Health Service Act (42 U.S.C. 274k(d)(2)) 
is amended by striking the second and third sentences in such 
subparagraph. 
(c) PERIODIC REVIEW OF STATE OF SCIENCE.—Section 379 of 
the Public Health Service Act (42 U.S.C. 274k) is amended by 
adding at the end the following new subsection: 
‘‘(o) PERIODIC REVIEW OF STATE OF SCIENCE.— 
‘‘(1) REVIEW.—Not less frequently than every 2 years, the 
Secretary, in consultation with the Director of the National 
Institutes of Health, the Commissioner of Food and Drugs, 
the Administrator of the Health Resources and Services 
Administration, the Advisory Council, and other stakeholders, 
where appropriate given relevant expertise, shall conduct a 
review of the state of the science of using adult stem cells 
and birthing tissues to develop new types of therapies for 
patients, for the purpose of considering the potential inclusion 
of such new types of therapies in the Program.
H. R. 941—2 
‘‘(2) RECOMMENDATIONS.—Not later than June 30, 2025, 
the Secretary shall— 
‘‘(A) complete the second review required by paragraph 
(1); and 
‘‘(B) informed by such review, submit to the Committee 
on Health, Education, Labor, and Pensions of the Senate 
and the Committee on Energy and Commerce of the House 
of Representatives recommendations on the appropriate-
ness of the inclusion of new types of therapies in the 
Program.’’. 
(d) AUTHORIZATION OF APPROPRIATIONS.—Section 379B of the 
Public Health Service Act (42 U.S.C. 274m) is amended by striking 
‘‘$33,000,000 for fiscal year 2015 and $30,000,000 for each of fiscal 
years 2016 through 2020’’ and inserting ‘‘$31,009,000 for each of 
fiscal years 2022 through 2026’’. 
SEC. 3. CORD BLOOD INVENTORY. 
Subsection (g) of section 2 of the Stem Cell Therapeutic and 
Research Act of 2005 (42 U.S.C. 274k note) is amended to read 
as follows: 
‘‘(g) AUTHORIZATION
OF APPROPRIATIONS.—To carry out this 
section, there is authorized to be appropriated $23,000,000 for each 
of fiscal years 2022 through 2026.’’. 
SEC. 4. ADVANCING THE FIELD OF REGENERATIVE MEDICINE. 
Section 402 of the Public Health Service Act (42 U.S.C. 282) 
is amended by adding at the end the following: 
‘‘(o) REGENERATIVE MEDICINE.—The Director of NIH shall, as 
appropriate, continue to consult with the directors of relevant 
institutes and centers of the National Institutes of Health, other 
relevant experts from such institutes and centers, and relevant 
experts within the Food and Drug Administration, to further the 
field of regenerative medicine using adult stem cells, including 
autologous stem cells, therapeutic tissue engineering products, 
human cell and tissue products, human gene therapies, and geneti-
cally modified cells.’’. 
SEC. 5. GAO REPORT ON REGENERATIVE MEDICINE WORKFORCE. 
Not later than 2 years after the date of enactment of this 
Act, the Comptroller General of the United States shall submit 
to the Committee on Health, Education, Labor, and Pensions of 
the Senate and the Committee on Energy and Commerce of the 
House of Representatives a report that assesses a specialized health 
care workforce in the field of regenerative medicine. The report 
shall include— 
(1) an overview of the current employment levels, in both 
commercial and academic settings, for— 
(A) positions necessary for the collection and transplan-
tation of stem cell therapeutics, including bone marrow 
and cord blood; and 
(B) positions in the field of regenerative medicine using 
adult stem cells and related to product development; 
(2) the identification of gaps, if any, in the projected 
workforce capacity for— 
(A) positions described in paragraph (1)(A); and 
(B) the field of regenerative medicine using adult stem 
cells, including workforce gaps related to the development 
of new cellular therapies using adult stem cells;